25 XP   0   0   10

Atara Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Atara Biotherapeutics Inc together

PenkeI guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

Quick analysis of Atara Biotherapeutics Inc (30 sec.)










What can you expect buying and holding a share of Atara Biotherapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$-0.94
Expected worth in 1 year
$-9.65
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-8.71
Return On Investment
-1,212.7%

For what price can you sell your share?

Current Price per Share
$0.72
Expected price per share
$0.4323 - $0.9375
How sure are you?
50%

1. Valuation of Atara Biotherapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$0.72

Intrinsic Value Per Share

$-23.23 - $-10.52

Total Value Per Share

$-24.17 - $-11.46

2. Growth of Atara Biotherapeutics Inc (5 min.)




Is Atara Biotherapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$99.2m$126.6m-$225.8m-227.6%

How much money is Atara Biotherapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$276.1m-$228.3m-$47.8m-17.3%
Net Profit Margin-3,220.9%-359.1%--

How much money comes from the company's main activities?

3. Financial Health of Atara Biotherapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#992 / 1010

Most Revenue
#436 / 1010

Most Profit
#930 / 1010

Most Efficient
#899 / 1010

What can you expect buying and holding a share of Atara Biotherapeutics Inc? (5 min.)

Welcome investor! Atara Biotherapeutics Inc's management wants to use your money to grow the business. In return you get a share of Atara Biotherapeutics Inc.

What can you expect buying and holding a share of Atara Biotherapeutics Inc?

First you should know what it really means to hold a share of Atara Biotherapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Atara Biotherapeutics Inc is $0.7186. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Atara Biotherapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Atara Biotherapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.94. Based on the TTM, the Book Value Change Per Share is $-2.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.50 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Atara Biotherapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.61-362.8%-2.61-362.8%-2.24-311.5%-2.81-390.9%-1.91-265.7%
Usd Book Value Change Per Share-2.18-303.2%-2.18-303.2%-1.50-209.0%-0.85-118.6%-0.08-11.5%
Usd Dividend Per Share0.000.0%0.000.0%0.010.9%0.022.8%0.011.4%
Usd Total Gains Per Share-2.18-303.2%-2.18-303.2%-1.50-208.1%-0.83-115.9%-0.07-10.2%
Usd Price Per Share0.51-0.51-3.28-11.13-17.59-
Price to Earnings Ratio-0.20--0.20--1.47--3.74--21.22-
Price-to-Total Gains Ratio-0.24--0.24--2.19--8.06--2.96-
Price to Book Ratio-0.55--0.55-2.64-3.59-7.94-
Price-to-Total Gains Ratio-0.24--0.24--2.19--8.06--2.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7186
Number of shares1391
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-2.18-0.85
Usd Total Gains Per Share-2.18-0.83
Gains per Quarter (1391 shares)-3,030.45-1,158.05
Gains per Year (1391 shares)-12,121.78-4,632.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-12122-12132110-4742-4642
20-24244-24254220-9485-9274
30-36365-36376330-14227-13906
40-48487-48498440-18969-18538
50-60609-60620550-23711-23170
60-72731-72742660-28454-27802
70-84852-84864771-33196-32434
80-96974-96986881-37938-37066
90-109096-109108991-42681-41698
100-121218-1212301101-47423-46330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%4.07.00.036.4%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%4.00.06.040.0%4.00.07.036.4%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%4.06.00.040.0%4.07.00.036.4%

Fundamentals of Atara Biotherapeutics Inc

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Fundamental data was last updated by Penke on 2024-04-11 01:23:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Atara Biotherapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -3,220.9% means that $-32.21 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -3,220.9%. The company is making a huge loss. -2
  • The TTM is -3,220.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-3,220.9%TTM-3,220.9%0.0%
TTM-3,220.9%YOY-359.1%-2,861.8%
TTM-3,220.9%5Y-2,776.9%-444.0%
5Y-2,776.9%10Y-1,388.5%-1,388.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,220.9%-200.1%-3,020.8%
TTM-3,220.9%-216.8%-3,004.1%
YOY-359.1%-288.3%-70.8%
5Y-2,776.9%-449.1%-2,327.8%
10Y-1,388.5%-605.5%-783.0%
1.1.2. Return on Assets

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • -166.8% Return on Assets means that Atara Biotherapeutics Inc generated $-1.67 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

  • The MRQ is -166.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -166.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-166.8%TTM-166.8%0.0%
TTM-166.8%YOY-60.7%-106.2%
TTM-166.8%5Y-87.4%-79.4%
5Y-87.4%10Y-62.5%-24.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-166.8%-13.3%-153.5%
TTM-166.8%-12.8%-154.0%
YOY-60.7%-11.7%-49.0%
5Y-87.4%-13.9%-73.5%
10Y-62.5%-15.7%-46.8%
1.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Atara Biotherapeutics Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-180.3%+180.3%
TTM-5Y-93.7%+93.7%
5Y-93.7%10Y-68.0%-25.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY-180.3%-15.1%-165.2%
5Y-93.7%-19.3%-74.4%
10Y-68.0%-20.2%-47.8%

1.2. Operating Efficiency of Atara Biotherapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Atara Biotherapeutics Inc is operating .

  • Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -3,141.0% means the company generated $-31.41  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

  • The MRQ is -3,141.0%. The company is operating very inefficient. -2
  • The TTM is -3,141.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,141.0%TTM-3,141.0%0.0%
TTM-3,141.0%YOY-441.2%-2,699.7%
TTM-3,141.0%5Y-2,791.4%-349.6%
5Y-2,791.4%10Y-1,395.7%-1,395.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,141.0%-296.2%-2,844.8%
TTM-3,141.0%-232.5%-2,908.5%
YOY-441.2%-298.2%-143.0%
5Y-2,791.4%-492.1%-2,299.3%
10Y-1,395.7%-632.4%-763.3%
1.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 32.41 means that the operating costs are $32.41 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 32.410. The company is inefficient in keeping operating costs low. -1
  • The TTM is 32.410. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ32.410TTM32.4100.000
TTM32.410YOY5.642+26.768
TTM32.4105Y29.227+3.183
5Y29.22710Y14.614+14.614
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.4103.231+29.179
TTM32.4103.310+29.100
YOY5.6423.890+1.752
5Y29.2275.739+23.488
10Y14.6147.876+6.738

1.3. Liquidity of Atara Biotherapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.72 means the company has $0.72 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.716. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.716. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.716TTM0.7160.000
TTM0.716YOY3.739-3.023
TTM0.7165Y4.367-3.650
5Y4.36710Y13.539-9.172
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7163.890-3.174
TTM0.7164.173-3.457
YOY3.7395.344-1.605
5Y4.3676.126-1.759
10Y13.5396.448+7.091
1.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.79 means the company can pay off $0.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.787. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.787. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.787TTM0.7870.000
TTM0.787YOY5.486-4.699
TTM0.7875Y6.810-6.024
5Y6.81010Y23.705-16.894
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7873.514-2.727
TTM0.7873.998-3.211
YOY5.4865.380+0.106
5Y6.8106.105+0.705
10Y23.7056.404+17.301

1.4. Solvency of Atara Biotherapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.60 means that Atara Biotherapeutics Inc assets are financed with 160.0% credit (debt) and the remaining percentage (100% - 160.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 1.600. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.600. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.600TTM1.6000.000
TTM1.600YOY0.664+0.936
TTM1.6005Y0.606+0.993
5Y0.60610Y0.345+0.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6000.339+1.261
TTM1.6000.336+1.264
YOY0.6640.271+0.393
5Y0.6060.366+0.240
10Y0.3450.389-0.044
1.4.2. Debt to Equity Ratio

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1.972-1.972
TTM-5Y0.620-0.620
5Y0.62010Y0.358+0.262
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM-0.402-0.402
YOY1.9720.335+1.637
5Y0.6200.426+0.194
10Y0.3580.461-0.103

2. Market Valuation of Atara Biotherapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.20 means the investor is paying $-0.20 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.276. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.197. Based on the earnings, the company is expensive. -2
  • The TTM is -0.197. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.276MRQ-0.197-0.079
MRQ-0.197TTM-0.1970.000
TTM-0.197YOY-1.465+1.269
TTM-0.1975Y-3.736+3.539
5Y-3.73610Y-21.217+17.481
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.276-2.264+1.988
MRQ-0.197-2.629+2.432
TTM-0.197-2.680+2.483
YOY-1.465-4.145+2.680
5Y-3.736-6.257+2.521
10Y-21.217-6.254-14.963
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.392. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.280. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.280. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.392MRQ-0.280-0.112
MRQ-0.280TTM-0.2800.000
TTM-0.280YOY-1.218+0.938
TTM-0.2805Y-5.240+4.961
5Y-5.24010Y-31.809+26.569
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.392-2.973+2.581
MRQ-0.280-3.333+3.053
TTM-0.280-3.553+3.273
YOY-1.218-5.605+4.387
5Y-5.240-8.376+3.136
10Y-31.809-8.865-22.944
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Atara Biotherapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.55 means the investor is paying $-0.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

  • The EOD is -0.767. Based on the equity, the company is expensive. -2
  • The MRQ is -0.547. Based on the equity, the company is expensive. -2
  • The TTM is -0.547. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.767MRQ-0.547-0.220
MRQ-0.547TTM-0.5470.000
TTM-0.547YOY2.642-3.189
TTM-0.5475Y3.588-4.135
5Y3.58810Y7.943-4.355
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.7671.896-2.663
MRQ-0.5472.115-2.662
TTM-0.5472.093-2.640
YOY2.6422.884-0.242
5Y3.5883.542+0.046
10Y7.9433.916+4.027
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

3.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 73.735% of the shares of Atara Biotherapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31EcoR1 Capital, LLC9.87720.13410067043100670430
2023-12-31BlackRock Inc6.95350.00017087213-608722-7.9097
2023-12-31Vanguard Group Inc6.55990.00016686043801101.2127
2023-09-30Redmile Group, LLC6.16240.442362808132326903.8473
2023-09-30D. E. Shaw & Co LP3.83670.0063910416-438912-10.0915
2023-12-31UBS Group AG3.62360.0006369322536347336214.0686
2023-12-31AQR Capital Management LLC2.8770.002829323102087858247.2441
2023-12-31Millennium Management LLC2.86590.000729209802593916793.0913
2023-12-31State Street Corporation2.73170.0001278420026151410.3665
2023-12-31JPMorgan Chase & Co2.14680.00012188044-6479550-74.756
2023-12-31Geode Capital Management, LLC2.10960.00012150150735753.5431
2023-12-31Morgan Stanley - Brokerage Accounts1.75950.00011793371-421314-19.0237
2023-12-31Acadian Asset Management LLC1.73230.003517655541231161230.3849
2023-09-30Citadel Advisors Llc1.63960.0005167114553786247.4605
2023-12-31Goldman Sachs Group Inc1.14240.00011164378-2960031-71.7686
2023-09-30Antipodean Advisors LLC0.98117.5826100000000
2023-12-31Staley Capital Advisers Inc0.98110.0255100000000
2023-12-31Northern Trust Corp0.82950.0001845427465055.821
2023-12-31GSA Capital Partners LLP0.76960.03387843677843670
2023-12-31Charles Schwab Investment Management Inc0.73110.0001745145-48412-6.1006
Total 60.31058.233261469824+10674393+17.4%

3.2. Funds holding Atara Biotherapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.27070.0001271023600
2024-03-28iShares Russell 2000 ETF2.01250.0026240210511580.0482
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.12310.001134052300
2023-12-31Vanguard Explorer Inv0.93240.0027111288200
2024-01-31Fidelity Small Cap Index0.81610.0025974144193332.0248
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.80220.0018957477253002.7141
2024-03-28iShares Russell 2000 Value ETF0.70630.0047842975-535-0.0634
2024-02-29JPMorgan US Small Company L0.4280.040551082800
2024-03-29Schwab US Small-Cap ETF™0.4060.00248461700
2024-02-29Fidelity Extended Market Index0.37340.0009445678-120427-21.2729
2023-12-31Vanguard Strategic Small-Cap Equity Inv0.33880.0139404425-95822-19.1549
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.30240.002636098200
2024-02-29Vanguard Russell 2000 ETF0.29750.0029355044276698.4518
2024-02-29SPDR® Russell 2000 US Small Cap ETF0.2610.0091311479158115.3476
2024-02-29Vanguard Health Care ETF0.23210.00127703314880.54
2023-12-31NT R2000 Index Fund - NL0.22790.00192720473640.134
2023-12-31NT R2000 Value Index Fund - NL0.2140.003525547400
2024-01-31Fidelity VIP Disciplined Small Cap Init0.20170.040924077800
2024-02-29Schwab Small Cap Index0.19740.003123564500
2023-09-30BlackRock Extended Mkt Composite0.19050.002422743617110.758
Total 12.3340.140114721808-123950-0.8%

3.3. Insider Transactions

Insiders are holding 6.347% of the shares of Atara Biotherapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-04Anhco NguyenSELL107460.72
2024-03-04Pascal TouchonSELL248440.72
2023-11-16Anhco NguyenSELL88560.39
2023-11-16Eric J HyllengrenSELL119580.39
2023-11-16Pascal TouchonSELL204090.39
2023-11-13Carol Giltner GallagherBUY1790200.22
2023-11-10William K HeidenBUY1000000.25
2023-08-16Amar MuruganSELL86721.65
2023-08-16Eric J HyllengrenSELL81861.65
2023-08-16Pascal TouchonSELL307661.65
2023-06-27Pascal TouchonSELL142911.66
2023-05-16Amar MuruganSELL83892.04
2023-05-16Eric J HyllengrenSELL79182.04
2023-05-16Pascal TouchonSELL297662.04

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.179-2.1790%-1.502-31%-0.852-61%-0.083-96%
Book Value Per Share---0.937-0.9370%1.242-175%2.087-145%2.210-142%
Current Ratio--0.7160.7160%3.739-81%4.367-84%13.539-95%
Debt To Asset Ratio--1.6001.6000%0.664+141%0.606+164%0.345+364%
Debt To Equity Ratio----0%1.972-100%0.620-100%0.358-100%
Dividend Per Share----0%0.006-100%0.020-100%0.010-100%
Eps---2.607-2.6070%-2.238-14%-2.809+8%-1.909-27%
Free Cash Flow Per Share---1.834-1.8340%-2.693+47%-2.196+20%-1.530-17%
Free Cash Flow To Equity Per Share---1.815-1.8150%-2.172+20%-0.675-63%-0.075-96%
Gross Profit Margin--1.0041.0040%1.000+0%1.001+0%1.000+0%
Intrinsic Value_10Y_max---10.518--------
Intrinsic Value_10Y_min---23.228--------
Intrinsic Value_1Y_max---1.431--------
Intrinsic Value_1Y_min---2.304--------
Intrinsic Value_3Y_max---4.012--------
Intrinsic Value_3Y_min---6.984--------
Intrinsic Value_5Y_max---6.247--------
Intrinsic Value_5Y_min---11.695--------
Market Cap73241149.200+26%54311673.60054311673.6000%334527200.000-84%1134902758.720-95%1792553819.360-97%
Net Profit Margin---32.209-32.2090%-3.591-89%-27.769-14%-13.885-57%
Operating Margin---31.410-31.4100%-4.412-86%-27.914-11%-13.957-56%
Operating Ratio--32.41032.4100%5.642+474%29.227+11%14.614+122%
Pb Ratio-0.767-40%-0.547-0.5470%2.642-121%3.588-115%7.943-107%
Pe Ratio-0.276-40%-0.197-0.1970%-1.465+645%-3.736+1799%-21.217+10687%
Price Per Share0.719+29%0.5130.5130%3.280-84%11.131-95%17.585-97%
Price To Free Cash Flow Ratio-0.392-40%-0.280-0.2800%-1.218+336%-5.240+1774%-31.809+11274%
Price To Total Gains Ratio-0.330-40%-0.235-0.2350%-2.193+832%-8.057+3323%-2.962+1158%
Quick Ratio--0.7870.7870%5.486-86%6.810-88%23.705-97%
Return On Assets---1.668-1.6680%-0.607-64%-0.874-48%-0.625-63%
Return On Equity----0%-1.8030%-0.9370%-0.6800%
Total Gains Per Share---2.179-2.1790%-1.496-31%-0.833-62%-0.073-97%
Usd Book Value---99231000.000-99231000.0000%126640000.000-178%212028600.000-147%224888200.000-144%
Usd Book Value Change Per Share---2.179-2.1790%-1.502-31%-0.852-61%-0.083-96%
Usd Book Value Per Share---0.937-0.9370%1.242-175%2.087-145%2.210-142%
Usd Dividend Per Share----0%0.006-100%0.020-100%0.010-100%
Usd Eps---2.607-2.6070%-2.238-14%-2.809+8%-1.909-27%
Usd Free Cash Flow---194200000.000-194200000.0000%-274623000.000+41%-225311200.000+16%-156715200.000-19%
Usd Free Cash Flow Per Share---1.834-1.8340%-2.693+47%-2.196+20%-1.530-17%
Usd Free Cash Flow To Equity Per Share---1.815-1.8150%-2.172+20%-0.675-63%-0.075-96%
Usd Market Cap73241149.200+26%54311673.60054311673.6000%334527200.000-84%1134902758.720-95%1792553819.360-97%
Usd Price Per Share0.719+29%0.5130.5130%3.280-84%11.131-95%17.585-97%
Usd Profit---276126000.000-276126000.0000%-228302000.000-17%-288433000.000+4%-195663100.000-29%
Usd Revenue--8573000.0008573000.0000%63573000.000-87%19207600.000-55%9603800.000-11%
Usd Total Gains Per Share---2.179-2.1790%-1.496-31%-0.833-62%-0.073-97%
 EOD+6 -2MRQTTM+0 -0YOY+10 -255Y+11 -2410Y+5 -30

4.2. Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.276
Price to Book Ratio (EOD)Between0-1-0.767
Net Profit Margin (MRQ)Greater than0-32.209
Operating Margin (MRQ)Greater than0-31.410
Quick Ratio (MRQ)Greater than10.787
Current Ratio (MRQ)Greater than10.716
Debt to Asset Ratio (MRQ)Less than11.600
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.668
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.438
Ma 20Greater thanMa 500.713
Ma 50Greater thanMa 1000.723
Ma 100Greater thanMa 2000.690
OpenGreater thanClose0.688
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Stockholder Equity 290,781171,558462,339-182,725279,614-152,974126,640-225,871-99,231
Net Debt  -60,181-127,182-187,363106,797-80,56659,328-21,23853,12331,885
Net Working Capital  236,249204,123440,372-161,537278,835-62,671216,164-256,521-40,357
Net Invested Capital  290,781171,558462,339-182,725279,614-152,974126,640-225,871-99,231
Total Other Income Expense Net 4,717-2,2702,447-2,08036751,85652,223-59,058-6,835



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets165,504
Total Liabilities264,735
Total Stockholder Equity-99,231
 As reported
Total Liabilities 264,735
Total Stockholder Equity+ -99,231
Total Assets = 165,504

Assets

Total Assets165,504
Total Current Assets101,869
Long-term Assets63,635
Total Current Assets
Cash And Cash Equivalents 25,987
Short-term Investments 25,884
Net Receivables 34,108
Inventory 9,706
Other Current Assets 6,184
Total Current Assets  (as reported)101,869
Total Current Assets  (calculated)101,869
+/-0
Long-term Assets
Property Plant Equipment 58,791
Long-term Assets Other 4,844
Long-term Assets  (as reported)63,635
Long-term Assets  (calculated)63,635
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities142,226
Long-term Liabilities122,509
Total Stockholder Equity-99,231
Total Current Liabilities
Short-term Debt 12,179
Accounts payable 3,684
Other Current Liabilities 48,530
Total Current Liabilities  (as reported)142,226
Total Current Liabilities  (calculated)64,393
+/- 77,833
Long-term Liabilities
Capital Lease Obligations 57,872
Long-term Liabilities Other 39,254
Long-term Liabilities  (as reported)122,509
Long-term Liabilities  (calculated)97,126
+/- 25,383
Total Stockholder Equity
Common Stock11
Retained Earnings -1,969,150
Accumulated Other Comprehensive Income -204
Other Stockholders Equity 1,870,112
Total Stockholder Equity (as reported)-99,231
Total Stockholder Equity (calculated)-99,231
+/-0
Other
Capital Stock11
Cash and Short Term Investments 51,871
Common Stock Shares Outstanding 105,912
Current Deferred Revenue77,833
Liabilities and Stockholders Equity 165,504
Net Debt 31,885
Net Invested Capital -99,231
Net Working Capital -40,357
Property Plant and Equipment Gross 74,660
Short Long Term Debt Total 57,872



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
> Total Assets 
4,290
51,828
106,122
324,975
263,914
217,779
391,839
342,942
588,120
468,127
376,420
165,504
165,504376,420468,127588,120342,942391,839217,779263,914324,975106,12251,8284,290
   > Total Current Assets 
4,242
51,808
106,026
324,597
260,553
172,190
321,489
272,992
523,273
384,621
295,080
101,869
101,869295,080384,621523,273272,992321,489172,190260,553324,597106,02651,8084,242
       Cash And Cash Equivalents 
4,207
51,615
21,897
23,746
47,968
79,223
60,698
74,317
200,404
106,084
92,942
25,987
25,98792,942106,084200,40474,31760,69879,22347,96823,74621,89751,6154,207
       Short-term Investments 
0
0
82,219
296,736
207,714
86,873
248,933
184,792
300,255
264,984
149,877
25,884
25,884149,877264,984300,255184,792248,93386,873207,714296,73682,21900
       Net Receivables 
0
0
0
0
0
0
0
0
1,250
986
40,221
34,108
34,10840,2219861,25000000000
       Other Current Assets 
35
193
1,910
4,115
4,871
6,094
11,858
13,883
21,364
12,567
10,308
6,184
6,18410,30812,56721,36413,88311,8586,0944,8714,1151,91019335
   > Long-term Assets 
48
20
96
378
3,361
45,589
70,350
69,950
64,847
83,506
81,340
63,635
63,63581,34083,50664,84769,95070,35045,5893,361378962048
       Property Plant Equipment 
9
8
48
270
3,259
44,129
68,576
68,183
62,820
79,939
74,322
58,791
58,79174,32279,93962,82068,18368,57644,1293,2592704889
       Other Assets 
39
12
48
108
102
1,460
1,774
1,767
14,330
3,567
7,018
0
07,0183,56714,3301,7671,7741,460102108481239
> Total Liabilities 
8,017
62,845
2,940
9,875
10,178
39,915
52,982
52,161
125,781
188,513
249,780
264,735
264,735249,780188,513125,78152,16152,98239,91510,1789,8752,94062,8458,017
   > Total Current Liabilities 
1,302
1,524
2,724
9,709
9,675
27,646
39,979
36,743
82,901
105,786
78,916
142,226
142,22678,916105,78682,90136,74339,97927,6469,6759,7092,7241,5241,302
       Short-term Debt 
0
0
0
0
0
500
0
1,581
1,985
2,753
13,640
12,179
12,17913,6402,7531,9851,581050000000
       Short Long Term Debt 
0
0
0
0
0
500
0
0
0
0
0
0
00000050000000
       Accounts payable 
121
606
440
1,445
2,778
14,711
3,719
7,963
7,118
17,368
6,871
3,684
3,6846,87117,3687,1187,9633,71914,7112,7781,445440606121
       Other Current Liabilities 
1,181
918
2,284
8,264
6,897
12,935
36,260
5,733
40,343
44,905
50,405
48,530
48,53050,40544,90540,3435,73336,26012,9356,8978,2642,2849181,181
   > Long-term Liabilities 
6,715
61,321
216
166
503
12,269
13,003
15,418
42,880
82,727
170,864
122,509
122,509170,86482,72742,88015,41813,00312,26950316621661,3216,715
       Long term Debt Total 
0
0
0
0
0
0
0
244
0
0
0
0
00002440000000
       Other Liabilities 
4
230
216
166
503
12,269
13,003
1,038
29,690
57,209
109,157
0
0109,15757,20929,6901,03813,00312,2695031662162304
> Total Stockholder Equity
-3,727
-11,017
103,182
315,100
253,736
177,864
338,857
290,781
462,339
279,614
126,640
-99,231
-99,231126,640279,614462,339290,781338,857177,864253,736315,100103,182-11,017-3,727
   Common Stock
1
1
2
3
3
3
5
6
8
9
10
11
11109865333211
   Retained Earnings -1,969,150-1,693,024-1,464,722-1,124,581-817,961-527,349-296,650-177,159-98,110-40,889-12,883-4,110
   Capital Surplus 
0
0
144,169
413,725
431,075
474,662
866,541
1,108,516
1,586,616
1,744,695
1,821,721
0
01,821,7211,744,6951,586,6161,108,516866,541474,662431,075413,725144,16900
   Treasury Stock000000000000
   Other Stockholders Equity 
382
1,865
139,169
413,725
431,075
474,662
866,541
1,108,516
1,586,616
1,744,695
1,821,721
1,870,112
1,870,1121,821,7211,744,6951,586,6161,108,516866,541474,662431,075413,725139,1691,865382



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue8,573
Cost of Revenue-8,886
Gross Profit-313-313
 
Operating Income (+$)
Gross Profit-313
Operating Expense-268,963
Operating Income-269,276-269,276
 
Operating Expense (+$)
Research Development219,166
Selling General Administrative50,908
Selling And Marketing Expenses1,111
Operating Expense268,963271,185
 
Net Interest Income (+$)
Interest Income4,797
Interest Expense-5,285
Other Finance Cost-1,432
Net Interest Income944
 
Pretax Income (+$)
Operating Income-269,276
Net Interest Income944
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-276,111-262,441
EBIT - interestExpense = -274,561
-276,111
-270,841
Interest Expense5,285
Earnings Before Interest and Taxes (EBIT)-269,276-270,826
Earnings Before Interest and Taxes (EBITDA)-264,447
 
After tax Income (+$)
Income Before Tax-276,111
Tax Provision-6
Net Income From Continuing Ops-290,248-276,117
Net Income-276,126
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses277,849
Total Other Income/Expenses Net-6,835-944
 

Technical Analysis of Atara Biotherapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Atara Biotherapeutics Inc. The general trend of Atara Biotherapeutics Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Atara Biotherapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Atara Biotherapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.8325 < 0.8896 < 0.9375.

The bearish price targets are: 0.5906 > 0.5686 > 0.4323.

Tweet this
Atara Biotherapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Atara Biotherapeutics Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Atara Biotherapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc. The current macd is -0.0053925.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Atara Biotherapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Atara Biotherapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Atara Biotherapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Atara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAtara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Atara Biotherapeutics Inc. The current adx is 19.89.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Atara Biotherapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Atara Biotherapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Atara Biotherapeutics Inc. The current sar is 0.80435879.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Atara Biotherapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Atara Biotherapeutics Inc. The current rsi is 51.44. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Atara Biotherapeutics Inc Daily Relative Strength Index (RSI) ChartAtara Biotherapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Atara Biotherapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Atara Biotherapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Atara Biotherapeutics Inc Daily Stochastic Oscillator ChartAtara Biotherapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Atara Biotherapeutics Inc. The current cci is -26.18685589.

Atara Biotherapeutics Inc Daily Commodity Channel Index (CCI) ChartAtara Biotherapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Atara Biotherapeutics Inc. The current cmo is 6.89326768.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Atara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAtara Biotherapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Atara Biotherapeutics Inc. The current willr is -59.1995842.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Atara Biotherapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Atara Biotherapeutics Inc Daily Williams %R ChartAtara Biotherapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Atara Biotherapeutics Inc. The current atr is 0.064329.

Atara Biotherapeutics Inc Daily Average True Range (ATR) ChartAtara Biotherapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Atara Biotherapeutics Inc. The current obv is -16,837,617.

Atara Biotherapeutics Inc Daily On-Balance Volume (OBV) ChartAtara Biotherapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Atara Biotherapeutics Inc. The current mfi is 51.98.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Atara Biotherapeutics Inc Daily Money Flow Index (MFI) ChartAtara Biotherapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Atara Biotherapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Atara Biotherapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.438
Ma 20Greater thanMa 500.713
Ma 50Greater thanMa 1000.723
Ma 100Greater thanMa 2000.690
OpenGreater thanClose0.688
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Atara Biotherapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Atara Biotherapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Atara Biotherapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Atara Biotherapeutics Inc.

Receive notifications about Atara Biotherapeutics Inc in your mailbox!